Clinical trials: Atherosclerotic Disease
Cardiovascular Risk, Obesity
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo.
- Trial name
- AMBIENCE (NCT07861100)
- Testing
- Zenagamtide
- Where
- 769 sites in United States, Argentina and 24 more
- Volunteers
- 8,500 people
- Sponsor
- Novo Nordisk A/S
Atherosclerosis, Peripheral Vascular Disease
A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System
The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native…
- Trial name
- STRIDES (NCT00475566)
- Testing
- Dynalink®-E everolimus-eluting peripheral stent, Dynalink®-E, everolimus-eluting peripheral stent
- Where
- 10 sites in Austria, Belgium and 2 more
- Volunteers
- 104 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease, Critical Limb Ischemia
Serranator Recoil Study
The study objective is to assess the ability to define and measure post treatment recoil in infrapopliteal arteries. Preliminary evidence as to the differences between serration angioplasty and standard balloon angioplasty as…
- Trial name
- NCT05161039
- Testing
- Serranator, POBA
- Where
- 2 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- Cagent Vascular LLC
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM (NCT00823212)
- Testing
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin
- Where
- 133 sites in United States, Australia and 15 more
- Volunteers
- 1,530 people
- Sponsor
- Boston Scientific Corporation
Intracranial Atherosclerosis
The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis
The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of symptomatic intracranial atherosclerotic stenosis.
- Trial name
- NCT05757505
- Testing
- Intracranial Stent (Tonbridge), Wingspan Stent System (Stryker Neurovascular)
- Where
- 13 sites in China
- Volunteers
- 200 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd
Coronary Atherosclerosis, Myocardial Infarction
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of…
- Conditions
- Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
- Trial name
- CANARY (NCT01268319)
- Testing
- Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Infraredx
Acute Coronary Syndrome
OPTIMIZE IDE for the Treatment of ACS
Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery…
- Trial name
- OPTIMIZE (NCT03190473)
- Testing
- DES
- Where
- 72 sites in United States, Japan and 1 more
- Volunteers
- 1,630 people
- Sponsor
- Svelte Medical Systems, Inc.
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Cardiovascular Disease
A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of…
- Trial name
- NCT01059682
- Testing
- Dalcetrapib
- Where
- 110 sites in United States, Canada and 3 more
- Volunteers
- 936 people
- Sponsor
- Hoffmann-La Roche
Coronary Arteriosclerosis
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
- Trial name
- NCT00240318
- Testing
- Rosuvastatin calcium
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Aortic Aneurysm, Thoracic, Descending Thoracic Aortic Dissection
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® TAG® Thoracic Endoprosthesis treating diseases of the thoracic aorta.
- Conditions
- Aortic Aneurysm, Thoracic, Descending Thoracic Aortic Dissection, Aortic Diseases, Aorta Thoracic; Traumatic Rupture
- Trial name
- NCT02266342
- Testing
- GORE® TAG® Thoracic Endoprostheses
- Where
- France
- Volunteers
- 154 people
- Sponsor
- W.L.Gore & Associates
Hypertriglyceridemia, Cardiovascular Diseases
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or…
- Conditions
- Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT05610280
- Testing
- Olezarsen
- Where
- 168 sites in United States, Bulgaria and 12 more
- Volunteers
- 1,478 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cardiovascular Diseases, Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS)…
- Conditions
- Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease
- Trial name
- NCT05566678
- Testing
- Cigarette, THS, Smoking Abstinence
- Sponsor
- Philip Morris Products S.A.
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Peripheral Vascular Disease
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
OSPREY is a multi-center, single arm, non-randomized, prospective clinical trial. Subjects will undergo a superficial femoral artery (SFA) stent procedure using the Misago™ Peripheral Self Expanding stent once all of the…
- Trial name
- OSPREY (NCT01118117)
- Testing
- Misago™ Self-Expanding Stent System
- Where
- 31 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Terumo Medical Corporation
Non-insulin-dependent Diabetes Mellitus
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration of the study will be approximately 60 weeks.
- Trial name
- NCT00231387
- Testing
- rosiglitazone
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Risk, Chronic Kidney Disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease, Inflammation
- Trial name
- ZEUS (NCT05021835)
- Testing
- Ziltivekimab B, Ziltivekimab C
- Where
- 1,073 sites in United States, Argentina and 36 more
- Volunteers
- 6,385 people
- Sponsor
- Novo Nordisk A/S
Thoracic Aortic Aneurysms, and Penetrating Atherosclerotic Ulcers
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
The purpose of this study is to evaluate the safety and efficacy of the Relay thoracic stent-graft system to treat thoracic aortic aneurysms.
- Trial name
- NCT00435942
- Testing
- Relay Thoracic Stent-Graft, Open Repair
- Where
- 27 sites in United States
- Volunteers
- 180 people
- Sponsor
- Bolton Medical
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
- Trial name
- OCEAN(a)-CCTA (NCT07293260)
- Testing
- Olpasiran
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 406 people
- Sponsor
- Amgen